BEIJING & SHANGHAI & HONG KONG -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, announced its successful listing on the Shanghai Stock Exchange STAR Market. This follows the Company’s listing on the Hong Kong Stock Exchange in September 2022 and marks a significant milestone in establishing Biocytogen as the first “H+A” dual-listed global drug innovator, reinforcing its mission to become the global headstream of new drugs.

The Company’s IPO price was set at 26.68 RMB per share, with an opening price of 58 RMB, representing a 117% increase over the offering price. Based on the opening price, Biocytogen’s market capitalization exceeds 25.9 billion RMB.

Biocytogen’s proprietary RenMice® platforms (RenMab™, RenLite®, RenNano®, RenTCR mimic™) enable the discovery of fully human monoclonal, bispecific, multispecific, ADC, VHH, and TCR mimic antibodies across more than 1,000 druggable targets. Leveraging a library of over one million authentic antibody sequences, these platforms provide partners with grab-and-go access to high-quality therapeutic molecules—significantly accelerating antibody drug discovery timelines. To date, the Company has advanced more than 40 PCC-to-IND stage assets and established over 280 global discovery partnerships, including more than 10 clinical or near-clinical programs successfully out-licensed. Complementing this, Biocytogen offers a globally leading portfolio of more than 4,390 off-the-shelf target-humanized mouse models, supporting the preclinical evaluation of bispecific antibodies, antibody-drug conjugates (ADCs), nucleic acid-based therapeutics, and other innovative modalities.

The successful STAR Market listing positions Biocytogen for further global expansion, platform commercialization, and strategic capital deployment. Leveraging the synergies of its “H+A” dual-listing structure, the Company will continue deepening collaborations with international partners, strengthening its technology platforms, and driving the discovery of novel therapies to benefit global healthcare.